KLONOPIN (clonazepam) · CHEPLAPHARM
KLONOPIN is FDA-approved to treat 7 conditions (same as CLONAZEPAM).
Details
- Status
- Discontinued
- First Approved
- 1975-06-04
- Routes
- ORAL
- Dosage Forms
- TABLET
KLONOPIN Approval History
What KLONOPIN Treats
7 indicationsKLONOPIN is approved for 7 conditions since its original approval in 1975. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Seizure Disorder
- Lennox-Gastaut Syndrome
- Akinetic Seizures
- Myoclonic Seizures
- Absence Seizures
- Panic Disorder
- Agoraphobia
Same approved indications as CLONAZEPAM (same active ingredient).
Clinical Trial Registry
12 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT06133114 | STUDY-22-01296 | Ph 4 | withdrawn | Psychopharmacological Treatment of Emotional Distress |
| NCT06357104 | SCI-CT-0001 | Ph 4 | completed | Detoxification From the Lipid Tract |
| NCT02913924 results posted | 7343 U54DA037842-01 | Ph 2 | completed | Effect of Clonazepam on Cannabis Withdrawal and Relapse in Treatment-seeking Patients |
| NCT00810316 | A6131015 | Ph 1 | completed | Evaluate Pharmacokinetics Of Two Different Pharmaceutical Oral Formulations Of Alprazolam And A Clonazepam Tablet In Mexican Healthy Population |
| NCT01870024 LORACLOFT | P110123 2012-003795-39 | Ph 3 | completed | Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus |
| NCT02134366 | EPC-1 | Ph 3 | terminated | Clobazam Use in Epilepsia Partialis Continua - Pilot Study |
| NCT02690844 | 1182108 | Ph 4 | withdrawn | Effectiveness of Mucolox® and Clonazepam in Treatment of Burning Mouth Syndrome |
| NCT03061136 KGB | YOJ0004ARC | Ph 4 | withdrawn | Clonazepam Effects on Brain Oscillations and Cognition in Schizophrenia |
| NCT02374567 GAP | GAP-2014 | Ph 3 | terminated | Pharmacovigilance in Gerontopsychiatric Patients |
| NCT02312908 | 14172EuiYakAn178 | Ph 2 | completed | Effect of Clonazepam on REM Sleep Behavior Disorder in Patients With Parkinsonism |
| NCT01291316 | GABA-SPUM | Ph 1, Ph 2 | completed | GABAergic Modulation in Pain Transmission in Human: Effect of the GABAA Agonist Clobazam on Peripheral and Central Sensitisation |
| NCT01011036 | 152/09 SNF SPUM no.33CM30_124117 | Ph 3 | completed | Effects of GABA-a-Agonists on Pain Mechanisms: An Experimental Study in Healthy Volunteers |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
KLONOPIN FDA Label Details
Indications & Usage
FDA Label (PDF)KLONOPIN is FDA-approved to treat 7 conditions — same approved indications as CLONAZEPAM.
Track KLONOPIN with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.